| 0.1003 -0.002 (-1.57%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.2 |
1-year : | 0.26 |
| Resists | First : | 0.17 |
Second : | 0.22 |
| Pivot price | 0.1 |
|||
| Supports | First : | 0.09 | Second : | 0.07 |
| MAs | MA(5) : | 0.1 |
MA(20) : | 0.1 |
| MA(100) : | 0.54 |
MA(250) : | 0.49 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.7 |
D(3) : | 28.2 |
| RSI | RSI(14): 28.2 |
|||
| 52-week | High : | 1.5 | Low : | 0.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ APLT ] has closed above bottom band by 37.5%. Bollinger Bands are 96.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.1 - 0.1 | 0.1 - 0.1 |
| Low: | 0.09 - 0.1 | 0.1 - 0.1 |
| Close: | 0.1 - 0.1 | 0.1 - 0.1 |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Tue, 16 Dec 2025
Here's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Fri, 12 Dec 2025
Applied Therapeutics To Be Acquired By Privately Held Cycle Group - Nasdaq
Thu, 11 Dec 2025
Cycle Pharmaceuticals to Acquire Applied Therapeutics - GlobeNewswire
Thu, 11 Dec 2025
Cycle Pharmaceuticals acquiring Applied Therapeutics - Seeking Alpha
Thu, 27 Nov 2025
Applied Therapeutics (APLT) Upgraded to Buy: Here's Why - Yahoo Finance
Thu, 20 Nov 2025
Applied Therapeutics explores strategic alternatives amid workforce cuts - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 144 (M) |
| Held by Insiders | 1.1847e+008 (%) |
| Held by Institutions | 5.3 (%) |
| Shares Short | 12,150 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.961e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 796.7 % |
| Return on Equity (ttm) | -88.4 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | 359.85 |
| Sales Per Share | -340.24 |
| EBITDA (p.s.) | -1.903e+007 |
| Qtrly Earnings Growth | -0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.49e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|